{{Rsnum
|rsid=36079186
|Gene=CYP2B6
|Chromosome=19
|position=41007013
|Orientation=plus
|GMAF=0.001377
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}{{PharmGKB
|RSID=rs36079186
|Name_s=CYP2B6*27, CYP2B6:593T>C, CYP2B6:M198T
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=PubMed ID:17235330
|Annotation=The CYP2B6*27 allele shows an 85% decrease in enzyme activity leading to high plasma levels of efavirenz in patients.
|Drugs=efavirenz
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162355645
}}

{{PMID Auto
|PMID=18728241
|Title=Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
|OA=1
}}

{{PMID Auto
|PMID=20723261
|Title=Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients.
|OA=1
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}